Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study
| العنوان: | Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study |
|---|---|
| المؤلفون: | Jingyuan Yang, Mingzhen Yuan, Song Xia, Youxin Chen, Erqian Wang |
| المصدر: | BMC Ophthalmology, Vol 19, Iss 1, Pp 1-9 (2019) BMC Ophthalmology |
| بيانات النشر: | BMC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Vascular Endothelial Growth Factor A, 0301 basic medicine, Visual acuity, genetic structures, VEGF receptors, Angiogenesis Inhibitors, Photodynamic therapy, 0302 clinical medicine, lcsh:Ophthalmology, Polypoidal choroidal vasculopathy, Peripheral Vascular Diseases, Anti vegf, biology, Real world outcomes, General Medicine, Middle Aged, Bevacizumab, Drug Therapy, Combination, Female, medicine.symptom, Research Article, medicine.medical_specialty, Combination therapy, Recombinant Fusion Proteins, Anti-vascular endothelial growth factor therapy, complex mixtures, 03 medical and health sciences, Ranibizumab, Internal medicine, medicine, Humans, Retinal pigment epithelium, Aged, Retrospective Studies, Analysis of Variance, Chinese population, Choroid, business.industry, Retrospective cohort study, Choroid Diseases, eye diseases, Ophthalmology, 030104 developmental biology, lcsh:RE1-994, 030221 ophthalmology & optometry, Combination group, biology.protein, business |
| الوصف: | Background To evaluate 5-year outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy and combination therapy of anti-VEGF agents and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) in a real-world Chinese population. Methods Retrospective study. Fifty-three eyes of 46 patients with subtype 1 and 2 PCV followed up for at least 60 months were grouped into three regimens: anti-VEGF monotherapy, PDT combining with anti-VEGF therapy initially, and PDT combining with deferred anti-VEGF therapy. Main outcome measure was best-corrected visual acuity (BCVA) using logarithm of minimal angle of resolution (logMAR). Results The mean BCVA of eyes with subtype 1 PCV (n = 28) deteriorated from 0.69 logMAR at baseline to 1.25 logMAR at months 60 (P = 0.001), while the mean BCVA of eyes with subtype 2 PCV (n = 25) sustained stable from 0.62 logMAR at baseline to 0.57 at months 60 (P = 0.654). No significant differences of visual outcomes were found between the 3 treatment regimens for subtype 1 PCV. Anti-VEGF monotherapy and initial combination treatment had better visual outcomes in eyes with subtype 2 PCV than deferred combination group during part of follow-up significantly. Initial combination group needed a less number of PDT than deferred combination group (P Conclusions Compared with subtype 1 PCV, subtype 2 PCV has a more favorable visual outcome in real world. All the regimens presented unfavorable visual outcomes for subtype 1 PCV. Anti-VEGF monotherapy and initial combination therapy should be superior to deferred combination therapy in the long-term management of subtype 2 PCV. Prospective randomized studies of larger size are needed to determine the long-term efficacy and safety of various treatment for PCV in real world. |
| اللغة: | English |
| تدمد: | 1471-2415 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aacc4f985c1819431b3eedbfa05cd939Test http://link.springer.com/article/10.1186/s12886-019-1245-4Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....aacc4f985c1819431b3eedbfa05cd939 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14712415 |
|---|